title: Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations.
abstract: Due to constant progress in oncology, survival rates of patients (children and adults) with cancer are increasing. Consequently, the reproductive future of young cancer patients needs to be addressed carefully. Fertility preservation techniques are available and issues such as the time available for fertility treatments, patients' age, presence of a partner and patients' personal wishes have to be considered. In Switzerland, a first therapeutic network (Réseau Romand de Cancer et Fertilité), was created in the French speaking part of Switzerland in 2006. Since 2010, a global Swiss network (FertiSave) has been created. The goal of these networks is to maximise the safety and efficacy of fertility preservation options offered to cancer patients without compromising their oncological prognosis. Patients' needs have to be identified, the therapeutic options evaluated rapidly and the optimal treatment promptly implemented in these urgent situations. This article reviews the fertility preservation options currently available and makes recommendations for different specific cancer situations, consistent with the latest scientific evidence and in general agreement with international recommendations.
authors.affiliation: Reproductive Medicine, Department of Gynaecology and Obstetrics, University Hospital CHUV, Lausanne, Switzerland. dorothea.wunder@chuv.ch
authors.forename: Dorothea
authors.initials: D
authors.lastname: Wunder
authors.forename: Lucien
authors.initials: L
authors.lastname: Perey
authors.forename: Chahin
authors.initials: C
authors.lastname: Achtari
authors.forename: Alexandra
authors.initials: A
authors.lastname: Ambrosetti
authors.forename: Marina
authors.initials: M
authors.lastname: Bellavia
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Delaloye
authors.forename: Dominique
authors.initials: D
authors.lastname: de Ziegler
authors.forename: Fabienne
authors.initials: F
authors.lastname: Gumy-Pause
authors.forename: Claudine
authors.initials: C
authors.lastname: Helg
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
authors.forename: Patrick
authors.initials: P
authors.lastname: Petignat
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Primi
authors.forename: Anne
authors.initials: A
authors.lastname: Rosselet-Christ
authors.forename: Khalil
authors.initials: K
authors.lastname: Zaman
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D015925:Cryopreservation / Q000379:methods; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D005602:France; D006801:Humans; D007246:Infertility / Q000139:chemically induced*; D007802:Language; D008297:Male; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects; D013557:Switzerland
chemical_list: D000970:Antineoplastic Agents